BIOMÉRIEUX : Invest Securities raises its target
"In parallel with the quarterly publication marked by a further outperformance in molecular diagnostics, the group presented attractive but unsurprising medium-term targets", judges the analyst.
While the CMD offers appreciable visibility on post-Covid prospects, Invest Securities corrects the margin dynamic by including a strong acceleration from 2026 onwards, marginally impacting its 2024-25 BNA.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
Go to the original article.
Contact us to request a correction